On the other hand, Kluge et al. [84] prospectively evaluated the correlation between tumor burden measured by Ga-PSMA-11 PET/CT and plasma ctDNA levels in patients with advanced metastatic prostate cancer (both hormone-sensitive and castration-resistant). Here, FOLH1 is linked to metastatic prostate carcinoma.